BioLife Solutions, Inc. $BLFS Stock Position Trimmed by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 26.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 212,159 shares of the medical equipment provider’s stock after selling 74,734 shares during the period. Russell Investments Group Ltd. owned approximately 0.44% of BioLife Solutions worth $4,570,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. acquired a new position in shares of BioLife Solutions during the first quarter worth approximately $30,789,000. Royal Bank of Canada boosted its position in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after acquiring an additional 617,320 shares during the period. Invesco Ltd. grew its stake in shares of BioLife Solutions by 9.6% in the first quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider’s stock worth $81,106,000 after purchasing an additional 311,585 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of BioLife Solutions by 22.2% during the second quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock valued at $13,751,000 after purchasing an additional 115,963 shares during the period. Finally, TD Asset Management Inc raised its stake in shares of BioLife Solutions by 271.7% during the second quarter. TD Asset Management Inc now owns 144,290 shares of the medical equipment provider’s stock valued at $3,108,000 after purchasing an additional 105,470 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Finally, Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.20.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $25.46 on Friday. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The company has a market capitalization of $1.23 billion, a P/E ratio of -363.66 and a beta of 1.93. The company’s 50 day simple moving average is $26.55 and its 200 day simple moving average is $24.37.

Insider Buying and Selling at BioLife Solutions

In related news, Director Amy Duross sold 2,000 shares of BioLife Solutions stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $27.00, for a total value of $54,000.00. Following the transaction, the director directly owned 22,687 shares in the company, valued at $612,549. The trade was a 8.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Greef Roderick De sold 31,165 shares of the company’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $25.33, for a total value of $789,409.45. Following the sale, the chief executive officer directly owned 389,998 shares of the company’s stock, valued at approximately $9,878,649.34. This represents a 7.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 935,727 shares of company stock worth $26,269,334. 2.20% of the stock is owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.